Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Agilent, SomaLogic in Proteomic Tech Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Agilent, SomaLogic in Proteomic Tech Pact

Expands access to SOMAscan discovery platform

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Agilent Technologies, Inc. and SomaLogic, Inc. have entered into an agreement to expand access to SomaLogic’s unbiased protein biomarker discovery platform. The companies will initially place SomaLogic’s SOMAscan proteomic assay, which employs custom Agilent microarrays in its workflow, in select academic and contract research centers. Terms of the agreement were not disclosed.
 
“This agreement will greatly enhance our current microarray offerings by expanding them into the rapidly growing proteomics market,” said Jacob Thaysen, vice president and general manager of Agilent’s Genomics Solutions Division. “SomaLogic’s cutting-edge proteomic technology makes them an ideal partner for us to increase our presence in this growing market.”
 
“Agilent’s custom microarrays have been a critical element in our development of the SOMAscan assay over the past several years,” said Larry Gold, Ph.D., chairman and chief executive officer of SomaLogic. “We are delighted that our partnership is expanding to make the technology even more accessible to researchers everywhere.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics